Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
14 January 2019 | Story Eugene Seegers | Photo Anja Aucamp
Study Bug Bites Historian Early
Prof Corene de Wet, South Campus researcher, is a dedicated historian and educator.

From a childhood dream of being a historian, to a decades-long educator and double doctorate-holder, Prof Corene de Wet has led an eventful life. Realising that her undergrad qualification on its own would not get her a job, she completed the Higher Diploma in Education at the then Potchefstroom University for Christian Higher Education. However, “just to buy some time for myself,” she decided to study part-time while teaching in Winburg.

Prof De Wet calls it “being bitten by the part-time study bug.” By 1991, she had obtained her BEd (an honours degree at the time), MEd, and DEd degrees. In 1999, she graduated with a PhD in History. Today, Prof De Wet is still a research associate on our South Campus.

Tremendous milestones and mentors

Dr Lynette Jacobs, co-researcher on several projects, says, “Prof De Wet was the first woman to receive a full professorship in the Faculty of Education, and the first woman in the faculty to obtain an NRF rating. She received her professorship at a time when the academic world belonged to men. She outclassed her peers, rising head and shoulders above the crowd.”

Prof De Wet says her superhero is Prof Daniella Coetzee, South Campus Principal and long-time colleague. “Prof Coetzee is a brilliant academic and organiser. She makes every member of her staff feel special. I am ever thankful that she saw the need for a researcher on the South Campus and that she appointed me in this position,” says Prof De Wet.

“She is a seasoned academic who
still enjoys international recognition.”
—Dr Lynette Jacobs.

Generational history and work ethic

Although much has changed in education since her initial research, Prof De Wet believes that both her doctoral dissertations still bear scrutiny. Regarding the zeitgeist and its impact on the written history of a nation, Prof De Wet says, “We regularly hear many voices today who say that history must be ‘rewritten’. My thesis dealt with exactly that: How different generations of historians wrote histories influenced by the spirit of the time, or by textbooks, or by their own political or world views, or their philosophy on life. Thus, different generations interpret the same events differently.”

During a career spanning more than four decades, Prof De Wet has upheld a strong work ethic. This has enabled her to maintain her C-rating as an NRF researcher. “If one doesn’t dare, if you are too afraid of critique or failure, you won’t get anywhere in academia,” she says, adding, “Criticism is part of academic life. Therefore, take chances, and learn from healthy, constructive criticism.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept